Bainco International Investors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Bainco International Investors’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-66	Closed	-$30K	–	87
2019 Q1	$30K	Hold	66	–	–	﹤0.01%	84
2018 Q4	$30K	Buy	66 +10	+18%	+$6.2K	0.01%	95
2018 Q3	$51K	Hold	56	–	–	0.01%	98
2018 Q2	$33K	Buy	+56	New	+$36.5K	﹤0.01%	98

Other funds holding HTGM

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bainco International Investors's HTGM Position: Q2 2019 in Review

Bainco International Investors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2019, closing a stake of 66 shares — an estimated $30K sold.

Bainco International Investors first reported a position in HTGM in Q2 2018 and held it in 4 quarters. The position peaked at $51K in Q3 2018. 43 funds tracked by Wall St. Rank hold HTGM as of Q2 2019.

Bainco International Investors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Bainco International Investors sold 66 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2019, an estimated $30K.
Bainco International Investors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2018 and held it in 4 quarters.
Bainco International Investors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $51K in Q3 2018.
43 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2019.

Based on Bainco International Investors's 13F filing for Q2 2019, filed 22 Jul 2019.